US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

1  2    4    6  7  8  9  10  
Traumatic Brain Injury Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... emerging therapies for Traumatic Brain Injury in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating ...  |  read more...
USD 670
Glioma Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing ...  |  read more...
USD 670
Attention Deficit Hyperactivity Disorder Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... market. It covers emerging therapies for Attention Deficit Hyperactivity Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying ...  |  read more...
USD 670
Central Nervous System Disorders Pipeline Highlights Database – 2015
11/5/2014 | published by: Fore Pharma
... Drug market. It covers emerging therapies for CNS indications in active clinical development stages including early and late stage clinical trials. Key indications covered in this report include Multiple Sclerosis, Depression, Alzheimer’s disease, Parkinson’s disease, ...  |  read more...
USD 2,800
Brain Ischemia-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Brain Ischemia. This report provides information on the therapeutic development based on the Brain Ischemia dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Global Epilepsy Market 2014-2018
11/5/2014 | published by: TechNavio - Infiniti Research Ltd.
... brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as occurs in majority of the cases, it is known as idiopathic epilepsy. Epilepsy ...  |  read more...
USD 2,500
Conference Documentation: Clinical Trials in CNS
11/11/2014 | published by: SMI Publishing, Ltd
... The economic and social costs of neurodegenerative disorders to society are huge. Many big pharmaceutical companies have moved away from CNS research. With this comes the need for new and improved therapies for treating neurodegenerative ...  |  read more...
USD 788.78
Cognitive Disorders-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Cognitive Disorders. This report provides information on the therapeutic development based on the Cognitive Disorders dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Mild Cognitive Impairment-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... all the pipeline drugs that fall under Mild Cognitive Impairment. This report provides information on the therapeutic development based on the Mild Cognitive Impairment dealing with all the pipeline drugs, comparative analysis at various stages ...  |  read more...
USD 1,250
Neuroblastoma-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... that fall under Neuroblastoma. This report provides information on the therapeutic development based on the Neuroblastoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, ...  |  read more...
USD 1,250
Diabetic Neuropathy-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Diabetic Neuropathy. This report provides information on the therapeutic development based on the Diabetic Neuropathy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Risperdal Consta LP-API Insights, 2014
11/21/2014 | published by: DelveInsight
... the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a ...  |  read more...
USD 500
Down Syndrome-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs that fall under Down Syndrome. This report provides information on the therapeutic development based on the Down Syndrome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, ...  |  read more...
USD 1,250
Major Depressive Disorder-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Mania-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Partial Seizure-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Psychosis-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Schizophrenia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
Tourette Syndrome Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Cannabinoid Receptor Type 1 (CB1) Agonists -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... of the report is to establish the understanding for all the pipeline drugs that fall under Cannabinoid Receptor Type 1 (CB1) Agonists. This report provides information on the therapeutic development based on the Cannabinoid Receptor ...  |  read more...
USD 1,250
Attention Deficit Hyperactivity Disorder (ADHD)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III ...  |  read more...
USD 2,000
Anxiety Disorders- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Major Depressive Disorder- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the ...  |  read more...
USD 2,000
Mania- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
Migraine- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
1  2    4    6  7  8  9  10